Adjusted EPS of $2.04 exceeded analyst estimates of $1.99. Revenue reached $22.5 billion, surpassing expectations by 0.4%. Sales in the Innovative Medicine and MedTech segments drove top-line growth.

Reports FY24 revenue $2.983M vs $0 last year. “Entering 2025 marks the next chapter for Prime Medicine (PRME) as we look to share initial data for our most advanced product candidate ...

Equities researchers at Chardan Capital issued their FY2025 earnings per share estimates for Prime Medicine in a report issued on Monday, March 10th. Chardan Capital analyst G. Livshits anticipates ...

Adjusted EPS was $0.31, significantly above the expected ... Fulgent Genetics is transitioning toward becoming a fully integrated precision medicine company. This strategic shift focuses on ...

Editas Medicine reported earnings per share of -76 cents. This was below the analyst estimate for EPS of -67 cents. The company reported revenue of $1.14 million. This was 85.63% worse than the ...